TAFRO syndrome with a rapid fatal course despite corticosteroid and tocilizumab therapy
Tóm tắt
TAFRO syndrome is a recently proposed subtype of multicentric Castleman’s disease. Some patients have a refractory and aggressively fatal course. Here we report a case of TAFRO syndrome with a rapid fatal course despite corticosteroid and tocilizumab therapy. A 68-year-old Japanese male suffered from abdominal pain, watery diarrhea, fever, and general fatigue. On the 12th hospital day, severe thrombocytopenia, anasarca, and renal failure developed. The histopathological findings of lymph node biopsy were indicative of MCD. Although corticosteroid and tocilizumab were administered, the patient died of multiple organ failure on the 30th hospital day. Autopsy findings revealed that inflammation due to TAFRO syndrome was suppressed but multiple infarctions progressed and became the direct cause of death. Our case suggested that TAFRO syndrome should not be excluded even if clinical findings are insufficient for the diagnostic criteria at the onset and that in patients with TAFRO syndrome who are at a high risk of thrombosis, multiple infarctions may become a direct cause of death.
Tài liệu tham khảo
Frizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202–1216
El-Osta HE, Kurzrock R (2011) Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 16:497–511
Takai K, Nikkuni K, Shibuya H, Hashidate H (2010) Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 51:320–325
Kawabata H, Takai K, Kojima M et al (2013) Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53:57–61
Masaki Y, Kawabata H, Takai K et al (2016) Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103:686–692
Iwaki N, Fajgenbaum DC, Nabel CS et al (2016) Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91:220–226
Fujiwara S, Mochinaga H, Nakata H et al (2016) Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103:718–723
Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y (2016) TAFRO syndrome successfully treated with tocilizumab: a case report and systematic review. Mod Rheumatol 17:1–6
Kawabata H, Kotani S, Matsumura Y et al (2013) Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52:1503–1507
Fajgenbaum DC, van Rhee F, Nabel CS (2014) HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123:2924–2933
Takai K, Nikkuni K, Momoi A, Nagai K, Igarashi N, Saeki T (2013) Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases. J Clin Exp Hematop 53:63–68
Tadokoro A, Kanaji N, Hara T et al (2016) An uncharted constellation: TAFRO syndrome. Am J Med 129:938–941
Masaki Y, Nakajima A, Iwao H et al (2013) Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia—a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53:79–85
Yamaga Y, Tokuyama K, Kato T et al (2016) Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome. Intern Med 55:185–190
Hiramatsu S, Ohmura K, Tsuji H et al (2016) Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39:64–71